跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Lormalzi Concentrate for Solution for Infusion 350mg/20mL - HSA Drug Approval Details
Approvals
/
HSA
/
Lormalzi Concentrate for Solution for Infusion 350mg/20mL
Approved
THERAPEUTIC
Lormalzi Concentrate for Solution for Infusion 350mg/20mL
Lilly France
🇸🇬 Health Sciences Authority
Approval Date
Mar 11, 2025
Approval ID
70e802b956227a6a
Company
Lilly France
Type
Therapeutic
Approval Details
Approval Id
70e802b956227a6a
Drug Name
Lormalzi Concentrate for Solution for Infusion 350mg/20mL
Product Name
Lormalzi Concentrate for Solution for Infusion 350mg/20mL
Approval Number
SIN17201P
Approval Date
2025-03-11
Registrant
DKSH SINGAPORE PTE. LTD.
Drug Type
Therapeutic
Forensic Classification
Prescription Only
Dosage Form
INFUSION, SOLUTION CONCENTRATE
Route Of Administration
INTRAVENOUS
Atc Code
N06DX05
Pharma Manufacturer Name
DKSH SINGAPORE PTE. LTD.
Company Detail Path
/organization/dksh-singapore-pte-ltd
Active Ingredients
Donanemab
350mg/20mL
Donanemab
350mg/20mL
Approved
Quick Info
Agency
HSA
Country
🇸🇬
Approval Date
Mar 11, 2025
Approval ID
70e802b956227a6a
Type
Therapeutic
Back to HSA Approvals
